Vimarsana
Biggest News Aggregation in the World

Page 44 - Genetics Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Genetics Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Genetics Inc Today - Breaking & Trending Today

Myriad Genetics (NASDAQ:MYGN) Stock Rating Upgraded by The Goldman Sachs Group - Vimarsana News

Myriad Genetics (NASDAQ:MYGN) Stock Rating Upgraded by The Goldman Sachs Group

The Goldman Sachs Group upgraded shares of Myriad Genetics (NASDAQ:MYGN – Get Rating) from a sell rating to a buy rating in a research note published on Tuesday morning, The Fly reports. The firm currently has $25.00 target price on the stock, up from their previous target price of $18.00. Other research analysts have also […]

Source: wkrb13.com
Global Next-Generation Breast Cancer Diagnostic and Screening Market Report 2023: Sector is Expected to Reach $9.8 Billion by 2032 at a CAGR of 12.57% - Vimarsana News

Global Next-Generation Breast Cancer Diagnostic and Screening Market Report 2023: Sector is Expected to Reach $9.8 Billion by 2032 at a CAGR of 12.57%

/PRNewswire/ -- The "Next-Generation Breast Cancer Diagnostic and Screening Market - A Global Market and Regional Analysis: Focus on Technology, Cancer...

Global Next-Generation Breast Cancer Diagnostic and - Vimarsana News

Global Next-Generation Breast Cancer Diagnostic and

Dublin, May 26, 2023 (GLOBE NEWSWIRE) -- The "Next-Generation Breast Cancer Diagnostic and Screening Market - A Global Market and Regional Analysis:...

Goldman Sachs Maintains Myriad Genetics Buy Recommendation – 24/7 Wall St. - Vimarsana News

Goldman Sachs Maintains Myriad Genetics Buy Recommendation – 24/7 Wall St.

Goldman Sachs has maintained coverage of Myriad Genetics with a Buy recommendation.

Next-Generation Breast Cancer Diagnostic and Screening - Vimarsana News

Next-Generation Breast Cancer Diagnostic and Screening

Global Next-Generation Breast Cancer Diagnostic and Screening Market to Reach $9,880.1 Million by 2032. Global Next-Generation Breast Cancer Diagnostic and...